Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.

Julia Simões Corrêa GalendiMaria Del Pilar Estevez DizStephanie StockDirk Müller

Published in: Applied health economics and health policy (2021)

Although there is no rigorous cost-effectiveness threshold in Brazil, the result of this cost-effectiveness analysis may support the inclusion of BRCA1/2 testing for women at high-risk of cancer in the SUS. The ICER calculated for the provision of genetic testing for BRCA1/2 approximates the cost-effectiveness threshold proposed by the World Health Organization (WHO) for low- and middle-income countries.

Keyphrases

breast cancer risk
polycystic ovary syndrome
pregnancy outcomes
papillary thyroid
cervical cancer screening
high throughput
type diabetes
palliative care
squamous cell
pregnant women
metabolic syndrome
insulin resistance
lymph node metastasis